FDA panel to spotlight BiDil

This Thursday an FDA panel will consider whether BiDil -- rejected eight years ago -- should become the first drug approved for one race. The agency panel will review a study of more than 1,000 patients showing that the drug significantly reduced hospitalizations and deaths among African-American heart failure patients. NitroMed says it simply followed the data, but critics contend that the drug raises questions about trial designs and marketing that will be debated for years to come.

- read this article from The New York Times for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.